{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:46:18Z","timestamp":1787244378812,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1124\/jpet.110.168385","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T21:56:25Z","timestamp":1282168585000},"page":"266-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders"],"prefix":"10.1016","volume":"335","author":[{"given":"Maoyin","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shougang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.168385_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/mol.105.014167","article-title":"Rational development of histone deacetylase inhibitors as anticancer agents: a review","volume":"68","author":"Acharya","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.110.168385_bib2","doi-asserted-by":"crossref","first-page":"28930","DOI":"10.1074\/jbc.M303113200","article-title":"Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors","volume":"278","author":"Antos","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.168385_bib3","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1093\/ndt\/gfn314","article-title":"Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis","volume":"23","author":"Arakawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.110.168385_bib4","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1080\/10428190400003267","article-title":"Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia","volume":"45","author":"Arora","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/jpet.110.168385_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.110.168385_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1359-6101(03)00060-1","article-title":"Cytokine regulation of pulmonary fibrosis in scleroderma","volume":"14","author":"Atamas","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1124\/jpet.110.168385_bib7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","article-title":"Role of transforming growth factor beta in human disease","volume":"342","author":"Blobe","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.110.168385_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/25166","article-title":"Regulation of activity of the transcription factor GATA-1 by acetylation","volume":"396","author":"Boyes","year":"1998","journal-title":"Nature"},{"key":"10.1124\/jpet.110.168385_bib9","doi-asserted-by":"crossref","first-page":"21819","DOI":"10.1073\/pnas.0911987106","article-title":"Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models","volume":"106","author":"Cao","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.168385_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","article-title":"Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy","volume":"269","author":"Carew","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.110.168385_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1677\/ERC-07-0096","article-title":"Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines","volume":"14","author":"Catalano","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1124\/jpet.110.168385_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"10.1124\/jpet.110.168385_bib13","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1128\/MCB.01776-08","article-title":"Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis","volume":"29","author":"Coward","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.110.168385_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1568-9972(03)00005-3","article-title":"Systemic sclerosis: current views of its pathogenesis","volume":"2","author":"Derk","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1124\/jpet.110.168385_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1124\/jpet.110.168385_bib16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.21497","article-title":"Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells","volume":"54","author":"Distler","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.110.168385_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jcb.20532","article-title":"Prospects: histone deacetylase inhibitors","volume":"96","author":"Dokmanovic","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1124\/jpet.110.168385_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00197165","article-title":"Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene","volume":"87","author":"D\u00f6rk","year":"1991","journal-title":"Hum Genet"},{"key":"10.1124\/jpet.110.168385_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/jme.1.02138","article-title":"Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis","volume":"38","author":"Ellmers","year":"2007","journal-title":"J Mol Endocrinol"},{"key":"10.1124\/jpet.110.168385_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1124\/jpet.110.168385_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(01)00429-4","article-title":"Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT\/N-CoR","volume":"9","author":"Fischle","year":"2002","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.110.168385_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"Gay","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.110.168385_bib23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.bbamcr.2007.05.016","article-title":"Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation","volume":"1773","author":"Glenisson","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.110.168385_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"issue":"Suppl 1","key":"10.1124\/jpet.110.168385_bib25","first-page":"S91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases","volume":"83","author":"Gottlicher","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1124\/jpet.110.168385_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1124\/jpet.110.168385_bib27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMra003200","article-title":"Idiopathic pulmonary fibrosis","volume":"345","author":"Gross","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.110.168385_bib28","doi-asserted-by":"crossref","first-page":"L864","DOI":"10.1152\/ajplung.00128.2009","article-title":"Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition","volume":"297","author":"Guo","year":"2009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1124\/jpet.110.168385_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157488809789649223","article-title":"Epigenetic modifications: new therapeutic targets in primary myelofibrosis","volume":"4","author":"Hemavathy","year":"2009","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1124\/jpet.110.168385_bib30","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/art.24494","article-title":"Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis","volume":"60","author":"Hemmatazad","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.110.168385_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.1780370218","article-title":"Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud\u2019s phenomenon","volume":"37","author":"Higley","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.110.168385_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1541-7786.MCR-04-0070","article-title":"Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB\/p65 DNA binding","volume":"3","author":"Hu","year":"2005","journal-title":"Mol Cancer Res"},{"key":"10.1124\/jpet.110.168385_bib33","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/art.22759","article-title":"Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis","volume":"56","author":"Huber","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.110.168385_bib34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/sj.jid.5700303","article-title":"Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo","volume":"126","author":"Ishida","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.110.168385_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","article-title":"Multiple proteolytic systems, including the proteasome, contribute to CFTR processing","volume":"83","author":"Jensen","year":"1995","journal-title":"Cell"},{"key":"10.1124\/jpet.110.168385_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0092-8674(02)01085-1","article-title":"Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation","volume":"111","author":"Jeong","year":"2002","journal-title":"Cell"},{"key":"10.1124\/jpet.110.168385_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.105.559724","article-title":"Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding","volume":"113","author":"Kee","year":"2006","journal-title":"Circulation"},{"key":"10.1124\/jpet.110.168385_bib38","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1074\/jbc.M209572200","article-title":"Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65","volume":"278","author":"Kiernan","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.168385_bib39","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1021\/jm030377q","article-title":"Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors","volume":"46","author":"Kim","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.110.168385_bib40","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","article-title":"Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression","volume":"65","author":"Komura","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.110.168385_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.110.168385_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1440-1797.2007.00881.x","article-title":"Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction","volume":"12","author":"Kuratsune","year":"2007","journal-title":"Nephrology"},{"key":"10.1124\/jpet.110.168385_bib43","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","article-title":"Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression","volume":"21","author":"Lagger","year":"2002","journal-title":"EMBO J"},{"key":"10.1124\/jpet.110.168385_bib44","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.110.168385_bib45","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.cellsig.2005.10.013","article-title":"Phosphatidylinositol 3-kinase\/Akt pathway is involved in transforming growth factor-beta1-induced phenotypic modulation of 10T1\/2 cells to smooth muscle cells","volume":"18","author":"Lien","year":"2006","journal-title":"Cell Signal"},{"key":"10.1124\/jpet.110.168385_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.yjmcc.2008.08.015","article-title":"Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin","volume":"45","author":"Liu","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.110.168385_bib47","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2165\/11315680-000000000-00000","article-title":"Histone deacetylase inhibitors: current status and overview of recent clinical trials","volume":"69","author":"Ma","year":"2009","journal-title":"Drugs"},{"key":"10.1124\/jpet.110.168385_bib48","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/01.RES.0000046452.67724.B8","article-title":"Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy","volume":"91","author":"Manabe","year":"2002","journal-title":"Circ Res"},{"key":"10.1124\/jpet.110.168385_bib49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt1272","article-title":"Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug","volume":"25","author":"Marks","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.110.168385_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1124\/jpet.110.168385_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: Potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1124\/jpet.110.168385_bib52","doi-asserted-by":"crossref","first-page":"F133","DOI":"10.1152\/ajprenal.00400.2009","article-title":"Histone deacetylase modulates the pro-inflammatory and fibrotic changes in tubulointerstitial injury","volume":"298","author":"Marumo","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.110.168385_bib53","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural-functional relationships in diabetic nephropathy","volume":"74","author":"Mauer","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.110.168385_bib54","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/01.CIR.98.24.2765","article-title":"Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo","volume":"98","author":"McEwan","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/jpet.110.168385_bib55","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.110.168385_bib56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/CAD.0b013e328012a5db","article-title":"Histone deacetylase inhibitors for epigenetic therapy of cancer","volume":"18","author":"Monneret","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1124\/jpet.110.168385_bib57","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.11157","article-title":"Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts","volume":"48","author":"Mori","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.110.168385_bib58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.510290328","article-title":"A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture","volume":"29","author":"Niki","year":"1999","journal-title":"Hepatology"},{"key":"10.1124\/jpet.110.168385_bib59","doi-asserted-by":"crossref","first-page":"F729","DOI":"10.1152\/ajprenal.00086.2009","article-title":"Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury","volume":"297","author":"Noh","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.110.168385_bib60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.20395","article-title":"Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients","volume":"112","author":"Osada","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1124\/jpet.110.168385_bib61","doi-asserted-by":"crossref","first-page":"F996","DOI":"10.1152\/ajprenal.00282.2009","article-title":"Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy","volume":"297","author":"Pang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.110.168385_bib62","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1042\/BJ20070282","article-title":"The epigenetic signature of CFTR expression is coordinated via chromatin acetylation through a complex intronic element","volume":"408","author":"Paul","year":"2007","journal-title":"Biochem J"},{"key":"10.1124\/jpet.110.168385_bib63","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.cell.2007.04.035","article-title":"HEF1-dependent Aurora A activation induces disassembly of the primary cilium","volume":"129","author":"Pugacheva","year":"2007","journal-title":"Cell"},{"key":"10.1124\/jpet.110.168385_bib64","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.168385_bib65","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI119788","article-title":"In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR","volume":"100","author":"Rubenstein","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.110.168385_bib66","doi-asserted-by":"crossref","first-page":"C259","DOI":"10.1152\/ajpcell.2000.278.2.C259","article-title":"Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR","volume":"278","author":"Rubenstein","year":"2000","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/jpet.110.168385_bib67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1054\/bjoc.2000.1327","article-title":"P21-dependent G(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228","volume":"83","author":"Sandor","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1124\/jpet.110.168385_bib68","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1124\/jpet.110.168385_bib69","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.272.5260.408","article-title":"A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p","volume":"272","author":"Taunton","year":"1996","journal-title":"Science"},{"key":"10.1124\/jpet.110.168385_bib70","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.110.168385_bib71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1124\/jpet.110.168385_bib72","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nm1552","article-title":"Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity","volume":"13","author":"Trivedi","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/jpet.110.168385_bib73","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/01.RES.0000129579.59664.9d","article-title":"Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1","volume":"94","author":"Verheule","year":"2004","journal-title":"Circ Res"},{"key":"10.1124\/jpet.110.168385_bib74","doi-asserted-by":"crossref","first-page":"46541","DOI":"10.1074\/jbc.M306381200","article-title":"Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3","volume":"278","author":"Viatour","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.168385_bib75","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1124\/jpet.110.168385_bib76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1183\/09031936.00084808","article-title":"Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis?","volume":"34","author":"Wang","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.110.168385_bib77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/156802609788085241","article-title":"Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders","volume":"9","author":"Wiech","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.110.168385_bib78","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1172\/JCI117866","article-title":"Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2","volume":"95","author":"Wilborn","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.110.168385_bib79","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1535-7163.MCT-05-0230","article-title":"Clinical translation of epigenetics in cancer: eN-CORe\u2013a report on the second workshop","volume":"4","author":"Zelent","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.110.168385_bib80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(02)00861-9","article-title":"Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy","volume":"110","author":"Zhang","year":"2002","journal-title":"Cell"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524460813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524460813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.168385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:20:17Z","timestamp":1740000017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524460813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0022356524460813"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.168385","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.168385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}